Olivier Choussy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olivier Choussy has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
D. Dehesdin
15 shared publications- Emmanuel Babin
Normandie univ, UNICAEN, Inserm U1086, ANTICIPE, Caen, France
10 shared publications A. Paviot
8 shared publicationsD Dehesdin
6 shared publicationsJ. Marie
5 shared publicationsA. Meyer
4 shared publications
Latest Publications
- 1 January 2015
- Vol. 11 (2) , 89-93
Cervical lymph node metastases and T1 squamous cell carcinoma of the lips.
The occurrence of cervical lymph node metastasis is a major prognostic factor for head and neck squamous cell carcinoma (SCC) of the lip. This study focuses on patients with T1 stage tumours,in order to describe the prevalence of metastatic lymphadenopathies. A multicenter retrospective study was performed in three tertiary care referral centers and included 59 patients surgically treated for T1 stage SCC of the lips from January 1996 to December 2006. This surgical treatment concerned the tumour, with cervical neck dissection when lymph node metastasis was suspected. Cervical lymph node metastasis was found and histologically proven in 7 patients (11.9% of the cases, pN+ group; 95% confidence interval, 3.6 to 20.2%) during follow-up, never at the time of diagnosis. Metastasis appeared 13.3 ± 7.9 months (min. 5.3 months, max. 29.1 months) after the initial treatment and involved the IB level in all cases. Tumour progression was significantly longer in the pN+ group compared to patients with no lymph node metastases (sN-group). The pN+ group also had a significantly higher proportion of poorly or moderately differentiated tumours, and a significant decrease in overall survival, disease-free survival, and disease-specific survival. Lymph node metastasis occurs in roughly 12% of T1 stage SCC of the lips, and the management of neck lymph node areas is necessary. A randomized trial is needed to determine the proportion of occult lymph node metastases in T1N0 patients and the impact of this therapeutic procedure on survival.
- 1 January 2015
- Vol. 11 (2) , 89-93
Cervical lymph node metastases and T1 squamous cell carcinoma of the lips.
The occurrence of cervical lymph node metastasis is a major prognostic factor for head and neck squamous cell carcinoma (SCC) of the lip. This study focuses on patients with T1 stage tumours,in order to describe the prevalence of metastatic lymphadenopathies. A multicenter retrospective study was performed in three tertiary care referral centers and included 59 patients surgically treated for T1 stage SCC of the lips from January 1996 to December 2006. This surgical treatment concerned the tumour, with cervical neck dissection when lymph node metastasis was suspected. Cervical lymph node metastasis was found and histologically proven in 7 patients (11.9% of the cases, pN+ group; 95% confidence interval, 3.6 to 20.2%) during follow-up, never at the time of diagnosis. Metastasis appeared 13.3 ± 7.9 months (min. 5.3 months, max. 29.1 months) after the initial treatment and involved the IB level in all cases. Tumour progression was significantly longer in the pN+ group compared to patients with no lymph node metastases (sN-group). The pN+ group also had a significantly higher proportion of poorly or moderately differentiated tumours, and a significant decrease in overall survival, disease-free survival, and disease-specific survival. Lymph node metastasis occurs in roughly 12% of T1 stage SCC of the lips, and the management of neck lymph node areas is necessary. A randomized trial is needed to determine the proportion of occult lymph node metastases in T1N0 patients and the impact of this therapeutic procedure on survival.
- 1 October 2014
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 131 (4) , A66-A67
Parathyroidectomie par cervicoscopie : notre expérience
- 1 October 2014
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 131 (4) , A66-A67
Parathyroidectomie par cervicoscopie : notre expérience
- 1 October 2014
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 131 (4) , A107
Lambeau fascio-cutané supra-claviculaire sensible : intérêt et technique
- 1 October 2014
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 131 (4) , A107
Lambeau fascio-cutané supra-claviculaire sensible : intérêt et technique
- 1 October 2014
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 131 (4) , A22
Exérèse endoscopique des cancers naso-sinusiens : notre expérience sur 10ans autour de 28 cas
- 1 October 2014
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 131 (4) , A22
Exérèse endoscopique des cancers naso-sinusiens : notre expérience sur 10ans autour de 28 cas
- 1 October 2014
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 131 (4) , A4
Efficacité et tolérance du bévacizumab (Avastin®) à 50mg et 100mg en spray nasal dans le traitement des épistaxis chroniques chez les patients atteints de la maladie de Rendu-Osler : 1 an après
- 1 October 2014
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 131 (4) , A4
Efficacité et tolérance du bévacizumab (Avastin®) à 50mg et 100mg en spray nasal dans le traitement des épistaxis chroniques chez les patients atteints de la maladie de Rendu-Osler : 1 an après
- 1 February 2014
- Published by Elsevier in European Annals of Otorhinolaryngology, Head and Neck Diseases
- Vol. 131 (1) , 7-13
BRAF mutation in papillary thyroid carcinoma: Predictive value for long-term prognosis and radioiodine sensitivity
- 1 February 2014
- Published by Elsevier in European Annals of Otorhinolaryngology, Head and Neck Diseases
- Vol. 131 (1) , 7-13
BRAF mutation in papillary thyroid carcinoma: Predictive value for long-term prognosis and radioiodine sensitivity
- 1 October 2013
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 130 (4)
Intérêt de l’IRM de perfusion et diffusion dans le bilan des masses parotidiennes
- 1 October 2013
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 130 (4)
Intérêt de l’IRM de perfusion et diffusion dans le bilan des masses parotidiennes
- 1 October 2013
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 130 (4)
Évaluation de la fonction des cellules natural killer chez les patients présentant un carcinome épidermoïde des voies aérodigestives supérieures en situation palliative, devant recevoir du cetuximab : une étude préliminaire
- 1 October 2013
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 130 (4)
Évaluation de la fonction des cellules natural killer chez les patients présentant un carcinome épidermoïde des voies aérodigestives supérieures en situation palliative, devant recevoir du cetuximab : une étude préliminaire
- 1 October 2013
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 130 (4)
Efficacité du protocole « Pentoclo » dans la prise en charge des ostéoradionécrose
- 1 October 2013
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 130 (4)
Efficacité du protocole « Pentoclo » dans la prise en charge des ostéoradionécrose
- 1 October 2013
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 130 (4)
Efficacité et tolérance du bévacizumab (Avastin®) à 50mg et 100mg en spray nasal dans le traitement des épistaxis chroniques chez les patients atteints de la maladie de Rendu-Osler
- 1 October 2013
- Published by Elsevier in Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale
- Vol. 130 (4)
Efficacité et tolérance du bévacizumab (Avastin®) à 50mg et 100mg en spray nasal dans le traitement des épistaxis chroniques chez les patients atteints de la maladie de Rendu-Osler